Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer

被引:26
作者
Qi, Wei-Xiang [1 ]
Shen, Zan [1 ]
Yao, Yang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Coll Med, People Hosp 6, Dept Oncol, Shanghai 200233, Peoples R China
关键词
Non-small-cell lung cancer; Second-line therapy; Docetaxel; Meta-analysis; PLATINUM-BASED CHEMOTHERAPY; RANDOMIZED PHASE-III; VANDETANIB PLUS DOCETAXEL; SINGLE-AGENT; COMBINATION CHEMOTHERAPY; SUPPORTIVE CARE; TRIAL; STATISTICS; IRINOTECAN; QUALITY;
D O I
10.1007/s00280-011-1678-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To compare docetaxel-based doublet with single-agent docetaxel as second-line treatment in non-small-cell lung cancer (NSCLC). Methods We systematically searched for randomized clinical trials that compared docetaxel-based doublet with single-agent docetaxel in patients with histologically proven non-small-cell lung cancer. The primary end point was overall survival (OS). Secondary end points were progression-free survival, overall response rate, 1-year survival rate, and grade 3 or 4 toxicity. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed by Stata version 10.0 software (Stata Corporation, College Station, TX, USA). Results Eight randomized clinical trials (totally 2,126 patients) were eligible. Meta-analysis showed that there was significant improvement in PFS (HR 0.81, 95% CI 0.69-0.96, P = 0.013) and overall response rate (OR 1.42, 95% CI 1.13-1.80, P = 0.03) in docetaxel-based doublet group, compared with docetaxel alone, though the pooled HR for overall survival (HR 0.93, 95% CI 0.80-1.07, P = 0.308) showed no significant difference between the two groups. However, there were more incidences of grade 3 or 4 neutropenia (OR 1.2, 95% CI 1.00-1.45, P = 0.05), thrombocytopenia (OR 4.53, 95% CI 1.75-11.75, P = 0.002), and diarrhea (OR 1.78, 95% CI 1.16-2.74, P = 0.008) in docetaxel-based doublet group. With regard to the risk of grade 3 or 4 anemia (OR 1.95, 95% CI 0.62-6.17, P = 0.25), fatigue (OR 1.09, 95% CI 0.75-1.59, P = 0.66), and nausea and vomiting (OR 1.75, 95% CI 0.78-3.91, P = 0.17), there was no significant difference between the two groups. Conclusions This was the first meta-analysis of docetaxel-based doublet versus single-agent docetaxel as second-line therapy in the treatment of non-small-cell lung cancer. The results indicated that docetaxel-based doublet therapy did not gain any benefit in survival but significantly improved PFS and better ORR versus single-agent docetaxel. However, more incidences of grade 3 or 4 neutropenia, thrombocytopenia, and diarrhea were observed in docetaxel-based doublet group.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 50 条
  • [21] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [22] Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis
    Li, Zhe
    Liu, Zhibao
    Wu, Yuanyuan
    Li, Huarui
    Sun, Zhen
    Han, Chenggang
    Zhang, Xiaoling
    Zhang, Jinghua
    [J]. THORACIC CANCER, 2021, 12 (21) : 2838 - 2848
  • [23] Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Kostopoulou, V
    Nikolaou, M
    Gaglia, A
    Koumpou, M
    Mylonakis, N
    Xiros, N
    Economopoulos, T
    Raptis, SA
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (02) : 294 - 299
  • [24] Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
    Takeda, K.
    Negoro, S.
    Tamura, T.
    Nishiwaki, Y.
    Kudoh, S.
    Yokota, S.
    Matsui, K.
    Semba, H.
    Nakagawa, K.
    Takada, Y.
    Ando, M.
    Shibata, T.
    Saijo, N.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (05) : 835 - 841
  • [25] A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients
    Mo, Hongnan
    Hao, Xuezhi
    Liu, Yutao
    Wang, Lin
    Hu, Xingsheng
    Xu, Jianping
    Yang, Sheng
    Xing, Puyuan
    Shi, Youwu
    Jia, Bo
    Wang, Yan
    Li, Junling
    Wang, Hongyu
    Wang, Ziping
    Sun, Yan
    Shi, Yuankai
    [J]. CANCER MEDICINE, 2016, 5 (06): : 1116 - 1124
  • [26] Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer
    Oka, M
    Fukuda, M
    Nagashima, S
    Fukuda, M
    Kinoshita, A
    Soda, H
    Doi, S
    Narasaki, F
    Suenaga, M
    Takatani, H
    Nakamura, Y
    Kawabata, S
    Tsurutani, J
    Kanda, T
    Kohno, S
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (06) : 446 - 450
  • [27] Docetaxel in the treatment of advanced non-small-cell lung cancer
    Saloustros, Emmanouel
    Georgoulias, Vassilis
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1207 - 1222
  • [28] Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
    G V Scagliotti
    A Szczesna
    R Ramlau
    F Cardenal
    K Mattson
    N Van Zandwijk
    A Price
    B Lebeau
    J Debus
    C Manegold
    [J]. British Journal of Cancer, 2006, 94 : 1375 - 1382
  • [29] Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
    Scagliotti, G. V.
    Szczesna, A.
    Ramlau, R.
    Cardenal, F.
    Mattson, K.
    Van Zandwijk, N.
    Price, A.
    Lebeau, B.
    Debus, J.
    Manegold, C.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1375 - 1382
  • [30] Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis
    Xu, Zheng
    Yi, Fengming
    Yu, Dongliang
    Xu, Jianjun
    Wei, Yiping
    Zhang, Wenxiong
    [J]. CANCER MEDICINE, 2019, 8 (02): : 629 - 642